Sign in

Tero Järvinen

@terojarvinen.bsky.social
27 followers 31 following 57 posts

Professor & Chief Surgeon Tero Järvinen, M.D., Ph.D. Orthopedic sports medicine surgeon who got into molecular cell biology of tissue regeneration

PostsRepliesMedia
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 02/10/2026
What do patients really want to know about recovery? Read more about the idea, our collaboration with Aalto University students, and the next steps: www.ficebo.com/post/how-can... Photo source: Aalto University
011
Reposted by Tero Järvinen
Timothy Caulfield @caulfieldtim.bsky.social · 13/09/2026
NO evidence this kinda DATA DATA DATA tech helps health outcomes. Wellness & longevity marketing push idea that more data is always better and empowering. Not true. How Oura’s rings found their way onto millions of fingers www.economist.com/business/202...
economist.com
How Oura’s rings found their way onto millions of fingers
Its business is booming as consumers look to take charge of their health
85713
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 13/09/2026
Meet Leo, research intern at FICEBO! This summer, upper secondary school student Leo worked on developing an online course on evidence-based medicine. #FICEBO #EvidenceBasedMedicine #ResearchInternship
011
Reposted by Tero Järvinen
Molecular Therapy Family of Journals @moltherapy.bsky.social · 10/09/2026
The latest issue of Molecular Therapy Advances features original research focused on a dual-AAV otoferlin gene therapy for congenital deafness, anti-CAR antibodies in patients treated with anti-BCMA CAR T cell therapy, and more. bit.ly/4cWWPVl
032
Reposted by Tero Järvinen
regenmedlab.bsky.social @regenmedlab.bsky.social · 04/09/2026
How do human large blood vessels respond to hypoxia? Paucity of evidence until large arteries & veins collected after severe lower extremity trauma reveal rapid, but transient intimal hyperplasia and adventitial angiogenesis from veins. @evborg.bsky.social @navbo.bsky.social rdcu.be/XyAQYUmiqQma
011
Reposted by Tero Järvinen
regenmedlab.bsky.social @regenmedlab.bsky.social · 03/09/2026
We are in Halo! Our drug screening technology for homing and tissue penetrating macrocyclic peptides based on in vivo phage display & microdialysis (www.life-science-alliance.org/content/8/5/...) & macrocyclic homing peptides for targeted drug delivery are presented. www.halo.science/profile/tero...
halo.science
Tero Järvinen's profile
Tero Järvinen is a Principal Investigator at Tampere University. Expertise in Biopharmaceutics, Cardiovascular, Molecular Biology. Explore collaboration opportunities on Halo Science.
011
Reposted by Tero Järvinen
MRC-LMB Cell Biology Division @cellbiol-mrclmb.bsky.social · 28/08/2026
Great tribute to the discovery by Barbara Pearce of clathrin, the first protein found to act in membrane traffic, along with her mentoring and support of the pioneers (many of whom were other women) who revealed the workings of this key player in cellular function.
03419
Reposted by Tero Järvinen
Traffic @traffic-journal.bsky.social · 28/08/2026
Happy 50th anniversary, Clathrin! onlinelibrary.wiley.com/doi/full/10.... @effc.bsky.social
03621
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 27/08/2026
FICEBO’s Thomas Ibounig co-authored a new JAMA Internal Medicine review with researchers Romi Haas and Rachelle Buchbinder from Monash University. Read more about the study and Thomas’s upcoming dissertation on our website: www.ficebo.com/post/new-rev...
011
Tero Järvinen @terojarvinen.bsky.social · 16/08/2026
"Fragile skin may benefit from decoration" commentary on @nystromlab.bsky.social publication on the potential of decorin-based therapeutics for the treatment of RDEB. @matrixbiologie.bsky.social @epidermophyte.bsky.social @charitydebra.bsky.social Take a look www.sciencedirect.com/science/arti...
sciencedirect.com
Fragile skin may benefit from decoration
All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
030
Tero Järvinen @terojarvinen.bsky.social · 16/08/2026
Together w. Dr. Y. Liao we wrote a commentary on @nystromlab.bsky.social publication on the potential of decorin-based therapeutics for the treatment of RDEB. Take a look at "Fragile skin may benefit from decoration" @matrixbiologie.bsky.social www.sciencedirect.com/science/arti...
010
Tero Järvinen @terojarvinen.bsky.social · 15/08/2026
Fragile skin may benefit from decoration: Molecular Therapy Advances www.cell.com/molecular-th...
cell.com
Fragile skin may benefit from decoration
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe hereditary blistering disorder characterized by fragility of the skin and mucous membranes due to mutations in the COL7A1 gene, which enco...
020
Reposted by Tero Järvinen
🦋MOM🦋 @momcjl.bsky.social · 28/07/2026
25886123446
Reposted by Tero Järvinen
James Ball @jamesrball.com · 15/07/2026
Honestly, the way the entire pub chants "wanker" any time Infantino appears on screen is truly heartwarming.
151156139
Tero Järvinen @terojarvinen.bsky.social · 18/06/2026
Hot off the press! We demonstrate in Cancer Res that the αv integrin- and neuropilin-1 (NRP-1)-dual targeting iRGD peptide (in phase II clinical trials) reverses some of these tumor microenvironment features by inhibiting TGF-β activation in the tumor: aacrjournals.org/cancerres/ar...
011
Reposted by Tero Järvinen
pipsasaharinen.bsky.social @pipsasaharinen.bsky.social · 15/06/2026
Glad to see @jci.org featuring our study on endothelial RTK/integrin crosstalk—where ANGPT2 simultaneously engages two receptors! Big thanks to @johannaivaska@bsky.social and all co-authors and funders. @HelsinkiUniMed @helsinkiuni doi.org/10.1172/JCI1... #vascularbiology
doi.org
JCI - Inactive β1-integrin acts as a junctional scaffold for angiopoietin/TIE2/FOXO1 signaling
063
Tero Järvinen @terojarvinen.bsky.social · 15/05/2026
Hot off the press! We demonstrate in @theaacr.bsky.social that the αv integrin- and neuropilin-1 (NRP-1)-dual targeting iRGD peptide (in phase II clinical trials) reverses some of these tumor microenvironment features by inhibiting TGF-β activation in the tumor aacrjournals.org/cancerres/ar...
041
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 13/05/2026
Congratulations to Tappara on the win once again! 🏆 We’re proud to see one of our researchers Raine Sihvonen celebrating with the team as Tappara’s doctor. Our researchers do many things, and supporting sports is one of them! #Tappara #Research #IceHockey #Orthopedics
122
Reposted by Tero Järvinen
Martin González-Rodriguez @immuno-martin.bsky.social · 08/05/2026
With some big delays, but it's nice to see the fruitful collaboration with @terojarvinen.bsky.social and @carolinacabalin.bsky.social out in a nice package!
262
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 07/05/2026
MedicalResearch.com now interview with Teppo Järvinen, Professor of Orthopaedics and Traumatology, University of Helsinki and HUS. You can find more information about the interview here: medicalresearch.com/nejm-arthros...
medicalresearch.com
NEJM: Arthroscopic Partial Meniscectomy Provided No Benefit Over Placebo Surgery and May Worsen Longterm Outcomes
This study contributes to the concept of medical reversal, where widely used treatments are shown to be ineffective or harmful when tested rigorously.
022
Reposted by Tero Järvinen
NEJM.org @nejm.org · 03/05/2026
In the FIDELITY trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and possible harm from the procedure. Full trial results: nej.md/48Pkwww #Orthopedics
The image is a quote on a purple background: "Taken together with other evidence, these findings arouse concern ... with regard to the use of arthroscopic partial meniscectomy for degenerative meniscal tear in middle-aged and older adults." Attributed to R. Kalske et al. Below is a reference to read more on NEJM.org.
1144
Reposted by Tero Järvinen
NEJM.org @nejm.org · 07/05/2026
Three must-read articles that sparked major news coverage in April.
053
Reposted by Tero Järvinen
Gareth Moore @garethmoore.bsky.social · 30/04/2026
Over the moon to see this work from my PhD finally published in Development! Using a combination of structural biology and genetics we identify an avidity-driven mechanism of BMP signal control in the extracellular space. (1/11)
33510
Tero Järvinen @terojarvinen.bsky.social · 30/04/2026
In 2002, I watched hundreds of surgeons jump out of their seats to blast a speaker. @nejm.org Arthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | New England Journal of Medicine www.nejm.org/doi/full/10....
nejm.org
Arthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | NEJM
In this trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and ...
111
Tero Järvinen @terojarvinen.bsky.social · 30/04/2026
Hot off the press! ☝️ Arthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | New England Journal of Medicine www.nejm.org/doi/full/10....
nejm.org
Arthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | NEJM
In this trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and ...
000
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 29/04/2026
www.nejm.org/doi/full/10....
nejm.org
Arthroscopic Partial Meniscectomy for Degenerative Tear — 10-Year Outcomes | NEJM
In this trial of arthroscopic partial meniscectomy for degenerative medial meniscal tear in adults, participant-reported and radiologic outcomes over 10 years of follow-up suggested no benefit and ...
022
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 29/04/2026
The FIDELITY 10-year results have been published in the New England Journal of Medicine. You can find the full article through the link in the comments. #FIDELITY #NEJM #MedicalResearch
121
Reposted by Tero Järvinen
Pirjo Toivonen @pirjot.bsky.social · 29/04/2026
A significant milestone for the field and a proud moment for everyone involved. ✨
011
Tero Järvinen @terojarvinen.bsky.social · 27/04/2026
Dr. Tuomas Komulainen, M.D. wrapped up his PhD Thesis demonstrating that the recruitment of anti-inflammatory M2 macrophages are important for keloid resolution after corticosteroids therapy. A double-blinded, randomized, controlled trial. @thejidjournal.bsky.social www.jidonline.org/article/S002...
jidonline.org
Anti-Inflammatory Macrophages Are Recruited to the Keloids that Obtain Response to Intralesional Injection Therapies: Before and After Treatment Biopsies from a Double-Blinded, Randomized, Controlled ...
We explored the predictive value of immune cell populations to intralesional injections using biopsies collected from the active border of keloids before and after injections in the double-blinded ran...
010
Reposted by Tero Järvinen
Pirjo Toivonen @pirjot.bsky.social · 24/04/2026
Have you heard about this? #TBT #ThrowBackThursday #EBM #placebo #RCT #FIDELITYtrial
011
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 23/04/2026
www.nejm.org/doi/10.1056/...
nejm.org
Arthroscopic Partial Meniscectomy versus Sham Surgery for a Degenerative Meniscal Tear | NEJM
Arthroscopic partial meniscectomy is one of the most common orthopedic procedures, yet rigorous evidence of its efficacy is lacking. We conducted a multicenter, randomized, double-blind, sham-contr...
021
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 23/04/2026
#TBT to one of our most widely recognized publications: the 1-year results of FIDELITY. Find the publication link in the comments.
121
Reposted by Tero Järvinen
DEBRA UK @charitydebra.bsky.social · 16/04/2026
Since our research programme began, we have invested an average of £500,000 a year in pioneering EB research - £24 million so far. This sustained commitment is accelerating treatment breakthroughs, improving quality of life & bringing us closer to a world where EB no longer limits lives. 🦋
011
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 15/04/2026
www.ficebo.com/post/ficebo-...
ficebo.com
FICEBO at Hemsedal 2026
011
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 12/04/2026
Welcoming a new junior researcher Venla-Linnea Karjalainen to the team. Venla-Linnea is a medical student at Tampere University and alongside her medical studies, she works on research in hand surgery and orthopaedics in FICEBO.
011
Tero Järvinen @terojarvinen.bsky.social · 10/04/2026
www.tuni.fi/en/news/tero... Honored to receive this recognition from Tampere Univ.🏆 This award belongs to the incredible team behind the work: Marianne Karlsberg, Toini Pemmari, Soili Lehtonen, and Ulrike May. Thanks to collaborators at @unitartupress.bsky.social (Teesalu Lab) and NYMC (Liao Lab).
tuni.fi
010
Tero Järvinen @terojarvinen.bsky.social · 10/04/2026
www.tuni.fi/fi/ajankohta...
tuni.fi
Tero Järvinen on Tampereen yliopiston Vuoden keksijä | Tampereen korkeakouluyhteisö
Epidermolysis bullosa on vakava harvinainen ihosairaus, joka vaikeissa tautimuodoissa johtaa kuolemaan jo vauvana ja lievemmissäkin muodoissa aggressiivisiin ihosyöpiin. Tampereen yliopiston Vuoden...
020
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 06/04/2026
In conversation with Jarkko Jokihaara. Interview by Alan Cassels. Read more on our website: www.ficebo.com/post/meet-dr...
011
Reposted by Tero Järvinen
Pirjo Toivonen @pirjot.bsky.social · 06/04/2026
Interview is particularly interesting, as Jarkko Jokihaara reflects on the history of trapeziectomy — and once again this reminds us why it is important to study the effectiveness of procedures already used in clinical practice.
011
Tero Järvinen @terojarvinen.bsky.social · 31/03/2026
Our work is out @eurjimmunol.bsky.social Dynamic Thymic Stromal Lymphopoietin and Its Receptor Complex Expression on Skin Langerhans Cells in Skin Inflammation - González‐Rodríguez - 2026 - European Journal of Immunology - Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
Dynamic Thymic Stromal Lymphopoietin and Its Receptor Complex Expression on Skin Langerhans Cells in Response to MC903‐induced Skin Inflammation
Thymic Stromal Lymphopoietin (TSLP) regulates the skin microenvironment during type 2 inflammation. Epidermal APCs, Langerhans cells (LCs), might be the target of TSLP, but whether LCs express CD127 ...
053
Reposted by Tero Järvinen
Timothy Caulfield @caulfieldtim.bsky.social · 30/03/2026
So much grift in stem cell space. Seeing more influencers leverage “regenerative” rhetoric. We been studying stem cell hype and unproven therapies for almost 20 yrs! And it just gets worse and worse. tbh, the phrase “stem cells” now a big red flag for BUNK! 🚩 🚩 🚩 🚩 🚩 🚩
5514
Reposted by Tero Järvinen
Pirjo Toivonen @pirjot.bsky.social · 30/03/2026
Great to be part of the team!✨
011
Reposted by Tero Järvinen
Timothy Caulfield @caulfieldtim.bsky.social · 03/03/2026
In this testing & data obsessed time, studies like this good reminder often useless & harmful! Over 40? Your rotator cuff probably looks a little rough www.sciencenews.org/article/shou... Study: "RC abnormalities nearly universal after age 40 years & routine imaging should NOT guide diagnosis..."
sciencenews.org
Over 40? Your rotator cuff probably looks a little rough
MRI scans of over 600 Finnish adults found that nearly all had frayed, torn or otherwise abnormal rotator cuffs — yet most had no symptoms.
12112
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 06/03/2026
“Almost as Common as Grey Hair” Recent study from our group finds that after midlife, rotator cuff changes on MRI are almost as expected as grey hair. Now the lead author Thomas Ibounig explains the recent FIMAGE study findings in depth: www.ficebo.com/post/almost-...
ficebo.com
“Almost as Common as Grey Hair”: New FICEBO study finds that after midlife, rotator cuff changes on MRI are almost as expected as grey hair
011
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 11/03/2026
You may have noticed a shift in our social media posts lately. That’s because Hongfei has joined our team to help share our research with a wider audience! Read more about Hongfei on our website: www.ficebo.com/people/hongf...
022
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 24/03/2026
Milloin valita olkamurtuman hoidoksi ortoosi ja milloin leikkaus? Tutkijamme arvioivat eri hoitomuotojen kustannusvaikuttavuutta FISH-tutkimuksessa, heidän kommenttinsa tuloksista voit lukea HUS uutisesta. ➡️ Verkkosivulla myös linkki alkuperäiseen tutkimusartikkeliin www.hus.fi/ajankohtaist...
hus.fi
Leikkaushoito on kustannustehokas vaihtoehto olkavarren murtumissa
Tutkimus osoittaa, että olkavarren murtuman leikkaushoito on yhteiskunnalle ortoosia edullisempi vaihtoehto. Lue, miten asiaa tutkittiin.
011
Reposted by Tero Järvinen
FICEBO @ficebo.bsky.social · 26/03/2026
We welcome our newest researcher to the team, Dr Amir Sobhani, bringing fresh perspectives and expertise to drive our work forward. Check out his full bio on our website: www.ficebo.com/people/amir-...
021
Tero Järvinen @terojarvinen.bsky.social · 12/03/2026
Shouldering uncertainty open.substack.com/pub/unrelent...
open.substack.com
Shouldering uncertainty
(03/09/2026) Week 196
000
Reposted by Tero Järvinen
JAMA Internal Medicine @jamainternalmed.com · 16/02/2026
#RotatorCuff abnormalities on #MRI were found in 99% of adults aged 41–76, including 96% of asymptomatic shoulders, indicating most findings are age-related rather than disease. ja.ma/4aiQPVU
A bar graph titled 'Figure 2. Bar Graph Showing the Prevalence of Rotator Cuff Abnormalities by Age and Sex' comparing female and male, includes age ranges from 41-44 to 70-76. It shows full-thickness tear, partial-thickness tear, tendinopathy and normal tendon.
111
Tero Järvinen @terojarvinen.bsky.social · 16/02/2026
Incidental Rotator Cuff Abnormalities on Magnetic Resonance Imaging url: jamanetwork.com/journals/jam...
020